Core Framework & Diagram Type 1 Diabetes
July 28, 20261 Min Read Multiple Sclerosis
July 28, 2026Your immune system mistakenly killed the only cells in your body that make insulin
—— Type 1 diabetes is not caused by eating too much sugar. It's a catastrophic error in identity recognition.
I. The day of diagnosis — the battle has usually been going on for years
On the day a type 1 diabetes patient is diagnosed, β cells have typically already been seventy to ninety percent destroyed. This means the immune war was quietly underway months to years before it was discovered. The patient may only have noticed they've been especially thirsty lately, always needing to use the bathroom, inexplicably losing a few kilograms. By the time these symptoms are obvious enough to warrant testing, β cells are nearly gone.
This finding comes from an important research project: TrialNet. This international research network tracked first-degree relatives of type 1 diabetes patients, periodically testing blood for autoantibodies, and discovered that the immune attack began long before clinical symptoms appeared. Detecting autoantibodies targeting β cells (anti-GAD65, anti-IA-2, anti-ZnT8) in blood is considered a prodromal marker for type 1 diabetes. A person can have positive antibodies for years with no blood sugar abnormalities — this discovery is changing our understanding of the intervention window.
2. Why does the immune system attack its own pancreatic islets?
This is the most central and most incompletely answered question in type 1 diabetes research. What we know: it involves the combined action of genetic and environmental dimensions.
Genetically, HLA genes are the most important risk factor. Specific HLA types (like HLA-DR3, HLA-DR4) are significantly associated with type 1 diabetes risk — these genes control how T cells recognize self versus non-self, and HLA variants affect the efficiency of the thymus's 'screening' of self-reactive T cells. But genetics isn't deterministic: even in identical twins, if one has type 1 diabetes, the other's risk is only thirty to fifty percent, indicating environmental factors carry substantial weight.
Environmentally, viral infection (especially enteroviruses like Coxsackievirus B) is considered one triggering factor — viral infection may trigger immune attack through 'molecular mimicry' (viral proteins structurally similar to β cell proteins, so the immune system mistakenly damages β cells while attacking the virus) or by directly infecting β cells. Early gut microbiome composition has also been found to correlate with type 1 diabetes risk. No single factor can completely explain all cases. The most honest answer: multiple factors working together, genetics providing the susceptibility floor, environmental factors pulling the trigger.
3. The silent 'sentinels' — autoantibodies
Before β cells are massively destroyed, the immune system has already left traces: autoantibodies. These antibodies are proof of erroneous immune activation. They may not directly kill β cells (the primary killers are cytotoxic T cells), but they're the earliest detectable signal in blood — discoverable years before clinical symptoms appear.
Currently most commonly used autoantibody tests include: anti-glutamic acid decarboxylase antibody (anti-GAD65), anti-tyrosine phosphatase antibody (anti-IA-2), insulin autoantibody (IAA), and anti-zinc transporter 8 antibody (anti-ZnT8). Detecting multiple positive antibodies carries extremely high risk of progressing to type 1 diabetes. TrialNet data shows children with two or more positive autoantibodies have over seventy percent probability of developing type 1 diabetes within ten years. This finding enabled 'staging' of type 1 diabetes: Stage 1 (antibody positive, blood sugar normal), Stage 2 (antibody positive, blood sugar starting to abnorm), Stage 3 (clinical symptoms appear, confirmed diagnosis).
4. The latest breakthrough: a drug that delays onset
In 2022, the US FDA approved an epoch-making drug: Teplizumab — the first drug approved to delay type 1 diabetes onset. Teplizumab is an anti-CD3 monoclonal antibody that, by modulating T cell activation, reduces the autoimmune attack on β cells. In the pivotal clinical trial, using Teplizumab in high-risk individuals in the prodromal phase (Stage 2) delayed progression to Stage 3 (clinical diagnosis) by an average of approximately two years.
This isn't a cure, but for a parent, giving a child two more years before needing daily insulin injections is enormously meaningful. This breakthrough represents a paradigm shift: type 1 diabetes can now be intervened in the prodromal phase, not only managed after diagnosis. Researchers continue exploring whether earlier intervention can achieve longer-lasting protection — and some research is attempting to regenerate already-damaged β cells.
5. Adult-onset type 1 diabetes: a long-misdiagnosed population
Something many doctors and patients don't realize: type 1 diabetes isn't only a childhood disease. Latent Autoimmune Diabetes of Adults (LADA) is an autoimmune diabetes that onsets in adulthood, progressing more slowly than childhood-onset type 1 diabetes. It presents more like type 2 diabetes — patients are often initially misdiagnosed as type 2 and treated with oral hypoglycemics, but the medication becomes progressively less effective — because β cells continue being slowly destroyed by the immune system.
LADA diagnosis requires testing autoantibodies (especially anti-GAD65) and C-peptide levels (reflecting residual β cell function). If an adult diabetic patient shows progressively worsening oral medication control, isn't overweight, and has no obvious metabolic syndrome features, LADA should be considered. LADA is estimated to account for five to ten percent of all adult diabetic patients, but the proportion correctly identified and diagnosed is far lower.
6. Living with type 1 diabetes: daily management through an immunological lens
Currently there's no cure for type 1 diabetes. Patients need to depend on exogenous insulin — through injection or insulin pump — for lifetime blood sugar stability. But 'management' has additional layers viewed through the immunological lens: type 1 diabetes patients are in a state of autoimmune activation, with chronically elevated inflammation levels, and complication development (nephropathy, retinopathy, neuropathy) is closely related to immune inflammation.
Therefore, managing blood sugar isn't only to avoid acute hyperglycemic complications. Strict blood sugar control simultaneously reduces chronic inflammation drivers, slows further depletion of residual β cell function, and reduces bystander damage from autoimmune activation to other organs. Exercise, sleep quality, stress management, gut health — these immune-influencing factors important for ordinary people are equally important for type 1 diabetes patients, and because their baseline immune state differs, the impact of these factors may be amplified.
7. The psychological burden of type 1 diabetes: the overlooked part
Type 1 diabetes is not only a physical disease. The continuous 'cognitive load' of daily blood sugar monitoring, carbohydrate counting, and insulin dose adjustments is genuine fatigue. Research shows depression and anxiety rates in type 1 diabetes patients are two to three times their peers, with a bidirectional relationship with blood sugar control quality: depression makes patients less able to maintain regular blood sugar management, while poor blood sugar control further aggravates the psychological burden.
'Diabetes Distress' is a psychological state specific to diabetes management — not entirely equivalent to clinical depression, but equally real and equally affecting quality of life and management effectiveness. Acknowledging this fatigue's existence and actively seeking psychological support are parts of type 1 diabetes long-term management that shouldn't be overlooked. Recent widespread adoption of continuous glucose monitoring (CGM) and closed-loop insulin delivery systems have made significant progress in relieving this management burden.
Frequently Asked Questions